Skip to main content
Fig. 1 (abstract P436). | Journal for ImmunoTherapy of Cancer

Fig. 1 (abstract P436).

From: 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part Two

Fig. 1 (abstract P436).

In vivo self-assembled albumin/vaccine nanocomplexes for lymph-node-targeted vaccine delivery in combination cancer immunotherapy. (a) Schematics of albumin-binding vaccine (AlbiVax) for LN-targeted vaccine delivery for cancer immunotherapy. (b, f) by PET imaging of radiolabeled AlbiVax in small animals, AlbiVax was systematically optimized for optimal LN-targeted delivery. (c, d) By light-sheet fluorescence imaging, we elucidated the distribution of AlbiVax in draining LNs that were cleared to be transparent. (e) By super-resolution imaging, we discovered efficient intracellular co-delivery of AlbiVax via mouse serum albumin (MSA) into endolysosome of bone marrow derived dendritic cells (BMDCs). (g) AlbiVax elicited 21-fold higher frequency of Antigen-specific CD8+ cytotoxic T lymphocytes (CTLs) than IFA-emulsified vaccine. (h-j) AlbiVax dramatically regressed or inhibited the progression of EG7.OVA (g), B16F10 (h), and MC38 tumors (i)

Back to article page